Hyderabad: Bharat Biotech, the manufacturer of Covaxin on Tuesday said that the supply price of the vaccine to the government of India at Rs. 150 per dose in not sustainable in the long run. Hence, a higher price is required from the private markets to offset part of the costs.
In a statement, it has invested over Rs.500 crore from its own resources for product development, clinical trials and setting up of manufacturing facility for producing Covaxin.
The company said, the weighted average price of Covaxin for all supplies realized by it is less than Rs.250 per dose. Going forward, 75 per cent of the capacity will be supplied to the government while rest 25 per cent will be sold to the private hospitals.
In April this year, Bharat Biotech had priced Covaxin at Rs.600 for state governments, Rs. 1200 for private hospitals and USD 15-20 for export. Later, it reduced the price for state governments to Rs. 400 per dose.
On June 7, the central government had announced procurement of 75 per cent of the vaccines for distribution to states. A day later the government placed orders for procurement of 44 crore doses including 19 crore doses of Covaxin.